Pharmaceutical Industry: 100% (2026)

Top 3 Markets:

1. USA: 40%
2. Europe: 35%
3. Latin America: 15%

Fagron NV is a leading company in the pharmaceutical industry specializing in the manufacturing and distribution of pharmaceutical formulations. The majority of revenues come from the pharmaceutical industry as Fagron offers products and services to pharmacies and hospitals.

The USA is the largest market for Fagron, driven by high demand for customized pharmaceutical solutions. Europe closely follows, benefiting from a strong presence in several European countries. Latin America is also a significant market characterized by growing interest in pharmaceutical formulations.

Production sites of Fagron NV:

Fagron NV produces its products at several locations worldwide to maximize its global presence and efficiency. The key production sites include:

• Europe: Fagron has multiple production facilities in Europe, including in the Netherlands and Belgium, which serve as central locations for the manufacturing and development of pharmaceutical raw materials and formulations.

• North America: In the USA, Fagron operates production plants focusing on the manufacturing of pharmaceutical products and formulations for the North American market.

• Latin America: Fagron also has production sites in Latin America, particularly in Brazil, to serve the local market and benefit from the growing demand in the region.

This strategic distribution of production sites enables Fagron to flexibly respond to market demands while optimizing supply chains.

Revenue Growth: 8.2% (2025)
R&D Investments: 10% of revenue (2025)

Fagron NV pursues a growth strategy that heavily focuses on innovation and expansion into new markets. The company continuously invests in research and development to expand its product range and offer new, innovative solutions in the field of pharmaceutical services and products.

Another key focus is on geographical expansion, particularly in emerging markets, to strengthen global presence. Fagron also relies on strategic acquisitions to solidify its market position and leverage synergies.

By combining these strategies, Fagron aims to further enhance its market leadership in the pharmaceutical services sector and achieve sustainable growth.

Main raw materials: Pharmaceutical active ingredients, excipients, packaging materials

Main importing countries: India, China, Germany

Fagron NV is a leading company in the field of pharmaceutical formulations and sources a variety of raw materials and materials for the production of its products. The main raw materials include pharmaceutical active ingredients and excipients needed for the manufacturing of extemporaneous medicines.

India and China are significant suppliers of pharmaceutical active ingredients, as these countries have strong production capacities and cost-effective manufacturing capabilities. Germany is another important partner, especially for high-quality excipients and packaging materials that must comply with strict European quality standards.

By diversifying its supply chains, Fagron NV can ensure supply security and optimize costs at the same time.

Market Share: Estimated 20% in the global market for pharmaceutical formulations (2026)

Research & Development: Investments of approximately 5% of revenue (2025)

Growth in Emerging Markets: 10% annual growth (2025)

Fagron NV has a significant competitive advantage in the field of pharmaceutical formulations. The company benefits from its strong market position and an estimated market share of 20% in the global market. This is supported by continuous investments in research and development, which account for about 5% of revenue.

Another advantage lies in the strategic expansion into emerging markets, where the company is experiencing an annual growth of 10%. These factors, combined with a strong brand presence and a wide product portfolio, sustainably strengthen the competitiveness of Fagron NV.

Institutional Investor Share: 65% (estimated for 2026)
Insider Buys/Sells: No significant transactions in the last year (2025)

The institutional investor share in Fagron NV is estimated to be around 65%. This demonstrates the confidence of institutional investors in the company's business model and market position. Institutional investors such as pension funds, investment funds, and other large financial institutions hold a significant portion of the shares, indicating a stable investor base.

In 2025, there were no significant insider transactions, neither in the form of large buys nor sells. This could suggest that the management and other insiders are satisfied with the current company strategy and market development. A lack of insider sells can also be interpreted as a positive signal, indicating confidence in the company's future growth.

Market share of Fagron NV: 8% (estimated, 2026)

Top competitors and their market shares:

1. B. Braun Melsungen AG: 15%
2. Fresenius Kabi AG: 14%
3. Baxter International Inc.: 12%
4. Grifols S.A.: 10%
5. Fagron NV: 8%
6. Lonza Group AG: 7%
7. Pfizer Inc.: 6%
8. Sanofi S.A.: 5%
9. Novartis AG: 4%
10. Teva Pharmaceutical Industries Ltd.: 3%

Fagron NV is a significant player in the field of pharmaceutical compounding and has secured a solid market share. Fagron's moat mainly lies in its specialization in personalized medicine and the production of tailored pharmaceutical solutions. This specialization allows Fagron to differentiate itself from generic manufacturers and meet specific customer needs.

Compared to larger competitors like B. Braun Melsungen and Fresenius Kabi, which have more comprehensive product portfolios and larger production capacities, Fagron's moat is less pronounced. These companies benefit from economies of scale and a broader international presence, giving them a competitive advantage.

Nevertheless, Fagron remains competitive through its innovation and focus on niche markets. To strengthen its moat, Fagron could invest in research and development as well as strategic partnerships to further expand its market position.

Revenue Growth: 8.2% (2025) EBITDA Margin: 18.5% (2025) Market Share in Europe: 22% (2025)

Fagron NV recorded a solid revenue growth of 8.2% in 2025, attributed to successful expansion into new markets and increased demand for its pharmaceutical services. The EBITDA margin of 18.5% indicates that the company operates efficiently and is able to manage its cost structure well.

The 22% market share in Europe highlights Fagron NV's strong position in a competitive market. This market position could help the company benefit from future growth opportunities in the region.

In summary, Fagron NV could be an attractive investment opportunity due to its solid financial performance and strong market position. However, investors should also consider other factors such as overall market trends and potential risks in the industry.

Dividend payment: 1.20 EUR per share (2026, estimated)
Dividend yield: 3.5% (2026, estimated)

Fagron NV has pursued a consistent dividend policy in recent years. The payouts have been regular, indicating a reliable dividend payment. The dividend yield of 3.5% is in the mid-range and is attractive to investors aiming for regular returns.

The company's financial stability and continuous cash flow generation support Fagron's ability to pay dividends. However, investors should keep an eye on the overall market development and specific company risks as these could influence the future dividend policy.